ArticleTranslational lung cancer research2022
Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China.
Article in Translational lung cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Modified Borg Scale (mBorg), the Numerical Rating Scale (NRS), and the Dyspnea- 12 Scale (D- 12): cross-scale comparison assessing the development of dyspnea in early-stage lung cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Clinical value of blood circulating tumor RNA (ctRNA) in liquid biopsy of lung cancer: a narrative review.Translational lung cancer research · 2026Review
- Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.JTO clinical and research reports · 2026Article
- Potential of quantitative X-ray imaging from photon-counting CT: A novel analysis based on effective atomic number and physical density.Journal of applied clinical medical physics · 2026Article
- Bronchoalveolar lavage microbiota signatures and stage-associated alterations in early-stage and advanced-stage non-small cell lung cancer: a pilot study.Journal of translational medicine · 2026Article
- LIMS2 downregulation is associated with tumor progression and immune landscape alterations in lung adenocarcinoma.Discover oncology · 2026Article
- Exploring the key clinical and computed tomography features for distinguishing high-grade lung cancers from morphologically similar benign tumors: a two-center case-control study.BMC medical imaging · 2026Article
- Personalized Conditional Survival Prediction for Patients with Early-Stage Non-small Cell Lung Cancer.Annals of surgical oncology · 2026Article
- Radiomics to understand pre-treatment tumor biology for resectable non-small cell lung cancer.Frontiers in oncology · 2026Review
- Attention-Enhanced Hybrid Bidirectional LSTM and Temporal Convolutional Network for Early Detection of Lung Cancer in Low-Dose CT Scans.Biomedical engineering and computational biology · 2026Article
- A comparative review of economic evaluations for immune checkpoint inhibitors in early stage and advanced stage cancer: focusing on pembrolizumab.Frontiers in pharmacology · 2026Review
- A lactylation-driven prognostic model for lung adenocarcinoma: cellular lactylation heterogeneity and immune insights.Translational lung cancer research · 2025Article
- [China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2025 Version)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study.Journal of immunotherapy and precision oncology · 2025Article
- Nodule Characteristics, Clinical Risk Factors, and Radiologist Experience as Predictors of Positive Baseline LDCT Screening Results.Healthcare (Basel, Switzerland) · 2025Article
- Tracing Metastatic Evolutionary Patterns in Lung Adenocarcinoma: Prognostic Dissection Based on a Multi-state Model.Cancer research and treatment · 2025Article
- MicroRNA‑21: A potential therapeutic target in lung cancer (Review).International journal of oncology · 2025Review
- Enhanced Malignancy Prediction of Small Lung Nodules in Different Populations Using Transfer Learning on Low-Dose Computed Tomography.Diagnostics (Basel, Switzerland) · 2025Article
- Comparative study of lung cancer care and survival outcomes across the Nordic countries.Acta oncologica (Stockholm, Sweden) · 2025Article
- Cost-effectiveness of risk model-based lung cancer screening in smokers and nonsmokers in China.BMC medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Representative prognostic data by clinical characteristics for lung cancer is not yet available in China. This study aimed to calculate the survival of lung cancer patients with different pathological evaluations, explore their predictive effects and provide information for prognosis improvement. Methods: In this multicenter cohort study, primary lung cancer patients diagnosed in 17 hospitals at three distinct levels in China between 2011-2013 were enrolled and followed up till 2020. Overall survival and lung cancer specific survival were calculated by Kaplan-Meier method. Cox proportional hazards model was applied to assess the effects of predictors of lung cancer survival. Results: Of all the 7,311 patients, the 5-year overall and lung cancer specific survival rates were 37.0% and 41.6%, respectively. For lung cancer patients at stages I, II, III, and IV, the 5-year overall survival rates were 76.9%, 56.1%, 32.6%, and 21.4%, respectively; the lung cancer specific survival rates were 82.3%, 59.7%, 37.2%, and 26.4%, respectively. Differences of survival for each stage remained significant between histological classifications (P<0.01). The 5-year overall survival rates for patients with squamous cell carcinoma, adenocarcinoma (AC), and small cell carcinoma were 36.9%, 43.3% and 27.9%, respectively; the corresponding disease-specific rates were 41.5%, 48.6% and 31.0%, respectively. Such differences were non-statistically significant at advanced stages (P=0.09). After multivariate adjustments, stage and classification remained independent predictors for the survival of lung cancer. Conclusions: The prognosis of lung cancer varied with the pathological stages and histological classifications, and had room for improvement. Stage was the strongest predictor, so efforts on early detection and treatment are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.